Literature DB >> 17705230

SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression.

Gunjan Malik1, Elizabeth Rojahn, Michael D Ward, Mathew B Gretzer, Alan W Partin, O John Semmes, Robert W Veltri.   

Abstract

BACKGROUND: We recently demonstrated the protein expression profiling of Dunning rat tumor cell lines of varying metastatic potential (G (0%), AT-1 ( approximately 20%), and MLL (100%)) using SELDI-TOF-MS. As a parallel effort, we have been pursuing the identification of the protein(s) comprising the individual discriminatory "peaks" and evaluating their utility as potential biomarkers for prostate cancer progression.
METHODS: To identify the observed SELDI-TOF-MS m/z (mass/charge) values with discriminatory expression between different sublines, we employed a combination of chemical pre-fractionation, liquid chromatography, gel electrophoresis and tandem mass spectroscopy. Identified proteins were then verified by immuno-assay and Western analysis.
RESULTS: A 17.5 K m/z SELDI-TOF-MS peak was found to retain discriminatory value in each of two separate study-sets with an increased expression in the metastatic MLL line. Sequence identification and subsequent immunoassays verified that Histone H2B is the observed 17.5 K m/z SELDI peak. SELDI-based immuno-assay and Western Blotting revealed that Histone H2B is specifically over-expressed in metastatic MLL lines.
CONCLUSIONS: SELDI-TOF MS analysis of the Dunning prostate cancer cell lines confirmed the consistent overexpression of a 17.5 K m/z peak in metastatic MLL subline. The 17.5 kDa protein from MLL has been isolated and identified as Histone H2B.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17705230     DOI: 10.1002/pros.20646

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  3 in total

1.  The knowledge-integrated network biomarkers discovery for major adverse cardiac events.

Authors:  Guangxu Jin; Xiaobo Zhou; Honghui Wang; Hong Zhao; Kemi Cui; Xiang-Sun Zhang; Luonan Chen; Stanley L Hazen; King Li; Stephen T C Wong
Journal:  J Proteome Res       Date:  2008-07-30       Impact factor: 4.466

Review 2.  Protein microarrays: novel developments and applications.

Authors:  Luis Berrade; Angie E Garcia; Julio A Camarero
Journal:  Pharm Res       Date:  2010-11-30       Impact factor: 4.200

3.  Nuclear morphometry, epigenetic changes, and clinical relevance in prostate cancer.

Authors:  Robert W Veltri; Christhunesa S Christudass
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.